HSDL1 and ovarian carcinoma: In ovarian cancer, various antigenic peptides containing tumor specific non-synonymous mutations (e.g. HSDL1 L25V) have been confirmed to be recognized by binding to HLA I molecules with high affinity in ovarian cancer cells, whereas the wild-type amino acid sequences appear to have relatively low binding affinity for the HLA I molecules18.